Cost utility analysis based on a head-to-head phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: A Canadian perspective

Value in Health

Volumn 14, Issue 5, 2011, Pages 652-656

  Pan, Feng ^a   Brazier, Nicole C ^b   Shear, Neil H ^c   Jivraj, Farah ^b   Schenkel, Brad ^d   Brown, Ruth ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Janssen Inc   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Johnson and Johnson Pharmaceutical Services   (United States)

Author keywords

Canada; cost utility analysis; Markov model; psoriasis

Indexed keywords

ETANERCEPT; USTEKINUMAB;

ADULT; CANADA; CONTROLLED STUDY; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG SENSITIVITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS VULGARIS; REVIEW;

EID: 80052493287     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.01.006     Document Type: Article

References (13)

1. C.E. Griffiths, B.E. Strober, and P. van de Kerkhof Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128 14
2. C.L. Leonardi, A.B. Kimball, and K.A. Papp Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674 (Pubitemid 351671883)
3. K.A. Papp, R.G. Langley, and M. Lebwohl Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684 (Pubitemid 351671884)
4. R.G. Langley, S.R. Feldman, and C. Han Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial J Am Acad Dermatol 63 2010 457 465
5. M. Lebwohl, K. Papp, and C. Han Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial Br J Dermatol 162 2010 137 146
6. Guidelines for the economic evaluation of health technologies: Canada, 3rd ed. http://www.cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf [Accesssed October 16, 2009]
7. NICE technology appraisal guidance 146 Adalimumab for the treatment of adults with psoriasis 2008 National Institute for Health and Clinical Excellence London, UK http://www.nice.org.uk/TA146 [Accessed on October 16, 2009]
8. N. Woolacott, N. Hawkins, and A. Mason Etanercept and efalizumab for the treatment of psoriasis: a systematic review Health Technol Assess 10 2006 1iv
9. Davie A, Brazier N, Tsao N, et al. Economic burden of moderate to severe chronic plaque psoriasis in Canada. ISPOR 14th Annual International Meeting, May 1620, 2009, Orlando, Florida
10. Ontario Health Insurance Plan Schedule of Benefits Physician Services 2009 Ministry of Health and Long Term Care, Government of Ontario, Canada Ontario
11. Ontario Health Insurance Plan Schedule of Benefits for Laboratory Services 1999 Ministry of Health and Long Term Care, Government of Ontario, Canada Ontario
12. A. Moore, K.B. Gordon, and S. Kang A randomized, open-labeled trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis J Am Acad Dermatol 56 2007 598 602
13. J.P. Ortonne, C. Griffiths, and E. Dadén Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate to severe psoriasis over 52 weeks: the CRYSTEL study Expert Rev Dermatol 3 2008 657 665